Post ACS Secondary Prevention Optimization Tool

Clinical calculation support · Verify results before clinical use

Clinical review checklist

Review secondary-prevention domains after acute coronary syndrome.

Guideline-informed review
Enter the patient’s current clinical features and documented care. The output is a checklist to support review, not a validated risk score or an automatic prescription recommendation.

Patient profile

Enter a value from 0 to 100.
Interpret alongside baseline LDL-C, treatment, adherence, and tolerance.

Clinical indications and safety considerations

Current treatment and care processes

Reset form

How to use the findings

Use the checklist to identify treatment and care-process items that may need discussion. Confirm each decision against the patient’s ACS presentation, revascularization status, time since event, renal function, potassium, blood pressure, bleeding risk, contraindications, medication tolerance, and preferences.

  • Antithrombotic treatment requires an individualized plan, particularly when oral anticoagulation or high bleeding risk is present.
  • After ACS, high-intensity statin therapy is recommended when tolerated. Consider nonstatin treatment according to LDL-C, existing therapy, and the applicable guideline.
  • RAAS inhibitors and MRAs depend on clinical indications, renal function, potassium, and contraindications.
  • Cardiac rehabilitation and smoking cessation support are important components of comprehensive secondary prevention.

Clinical references

Rao SV, et al. 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes. J Am Coll Cardiol. 2025.

doi:10.1016/j.jacc.2024.11.009

Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023.

doi:10.1093/eurheartj/ehad191

Disclaimer: This tool is intended for healthcare professionals as a clinical review aid. It does not replace guideline review, individualized clinical judgement, shared decision-making, or local protocols. A treatment being absent from the checklist does not automatically mean it should be prescribed, and a treatment being present does not establish that it is appropriate or adequately dosed.